HealthQuill Cellular Process
Austria’s Cyprumed GmbH has announced a license and option agreement with Merck & Co., to develop oral formulations of the US-based company’s peptides for an upfront payment of $493 million.
Drugs Health Medical

Austria’s Cyprumed in $493 million pact with Merck to develop peptides

HQ Team April 17, 2025: Austria’s Cyprumed GmbH has announced a license and option agreement with Merck & Co., to develop oral formulations.

Read More